Advertisement

Medical Oncology

, Volume 28, Issue 4, pp 1027–1031 | Cite as

Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors

  • Ji Li
  • Guopei Luo
  • Deliang FuEmail author
  • Chen Jin
  • Sijie Hao
  • Feng Yang
  • Xiaoyi Wang
  • Lie Yao
  • Quanxing Ni
Original paper

Abstract

The aim of this study is to summarize the experience of preoperative diagnosis for nonfunctioning pancreatic neuroendocrine tumors (NFPNETs). The medical records of patients with NFPNETs were identified from 2001 to 2009 in a single center. They were all reviewed and analyzed for their demographics, clinical presentation, preoperative laboratory evaluation and radiographic characterization. Twenty-six patients (11 men and 15 women) in the past 8 years were diagnosed with NFPNETs. Almost all patients had the normal level of exocrine tumor markers. Although it was not difficult to find tumors by traditional imaging modalities including CT and MRI, the misdiagnosis rate was as high as 81.2%. Perfusion CT was helpful to predict the biological behavior of tumors and even identified NFPNETs as benign or malignant. The preoperative diagnosis for NFPNETs can be confirmed by one or the combination of CgA, perfusion CT, FNA-EUS, PET and octreoscans. NFPNETs should be aroused suspicion of normal exocrine tumor markers and relative specific imaging appearance, which can be proved by one or the combination of CgA, perfusion CT, FNA-EUS, PET and octreoscans.

Keywords

Diagnosis Pancreatic tumors Pancreatic neuroendocrine tumors Nonfunctioning pancreatic neuroendocrine tumors Perfusion CT 

Notes

Acknowledgments

This work was supported by the Opening Foundation of Institute of Biomedical Sciences, Fudan University and the Science and Technology Commission of Shanghai Municipality (No 08411954300).

References

  1. 1.
    Eriksson B, Oberg K. Neuroendocrine tumours of the pancreas. Br J Surg. 2000;87:129–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Modlin IM, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Dralle H, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Fjallskog ML, et al. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Nomura N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Eckhauser FE, et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery. 1986;100:978–88.PubMedGoogle Scholar
  7. 7.
    Grant CS. Surgical management of malignant islet cell tumors. World J Surg. 1993;17:498–503.PubMedCrossRefGoogle Scholar
  8. 8.
    Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res. 2004;120:139–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Nguyen SQ, et al. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol. 2007;96:397–403.PubMedCrossRefGoogle Scholar
  10. 10.
    Norton JA et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057–1063; discussion 1063–1055.Google Scholar
  11. 11.
    Solorzano CC, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Degorce F, et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145–245). Br J Cancer. 1999;79:65–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Procacci C, et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol. 2001;11:1175–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–49.PubMedCrossRefGoogle Scholar
  15. 15.
    Kent RB 3rd, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981;193:185–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Skogseid B et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998;22:673–677; discussion 667–678.Google Scholar
  17. 17.
    Briganti V, et al. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm. 2001;16:515–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Sundin A, et al. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:246–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Anderson MA, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Jani N, et al. EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc. 2008;67:44–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Gines A, et al. Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. Gastrointest Endosc. 2002;56:291–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003;76 Spec No 1:S36–42.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ji Li
    • 1
  • Guopei Luo
    • 2
  • Deliang Fu
    • 1
    Email author
  • Chen Jin
    • 1
  • Sijie Hao
    • 1
  • Feng Yang
    • 1
  • Xiaoyi Wang
    • 1
  • Lie Yao
    • 1
  • Quanxing Ni
    • 2
  1. 1.Department of Pancreatic Surgery, General SurgeryHuashan HospitalShanghaiChina
  2. 2.Pancreatic Disease InstituteFudan UniversityShanghaiChina

Personalised recommendations